Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

CAMPRAL

ACAMPROSATE CALCIUM

Standard Dose
333MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview CAMPRAL is listed in Drugs@FDA under application 021431 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient ACAMPROSATE CALCIUM Form and strength TABLET, DELAYED RELEASE;ORAL - 333MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor FOREST LABS Submission history Latest submission status date: 2015-08-10 00:00:00.

Structured Monograph

Clinical summary

Approval overview CAMPRAL is listed in Drugs@FDA under application 021431 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient ACAMPROSATE CALCIUM Form and strength TABLET, DELAYED RELEASE;ORAL - 333MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor FOREST LABS Submission history Latest submission status date: 2015-08-10 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.